Management of potentially resectable colorectal cancer liver metastases

Table 2 Phase III trials of adjuvant chemotherapy after resection of colorectal liver metastases

Ref	n	CHT	Median PFS (mo)	Median OS (mo)
Langer et al[26]	129	5-FU/LV	No difference	No difference
Portier et al[27]	173	5-FU/LV	24.4 vs 16.6 (P = 0.028)	62.1 vs 46.4 (P = 0.13)
Mitry et al[28]	278	5-FU/LV	27.9 vs 18.8 (P = 0.059)	61.1 vs 46.9 (P = 0.125)
Ychou et al[31]	306	FOLFIRI vs 5-FU/LV	24.7 vs 21.6 (P = 0.44)	No difference

CHT: Chemotherapy; PFS: Progression free survival; OS: Overall survival; 5-FU/LV: 5-fluorouracil/Leucovorin; FOLFIRI: 5-FU/LV/Irinotecan.